Gold nanotheranostics: Proof-of-concept or clinical tool?

117Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

Abstract

Nanoparticles have been making their way in biomedical applications and personalized medicine, allowing for the coupling of diagnostics and therapeutics into a single nanomaterial—nanotheranostics. Gold nanoparticles, in particular, have unique features that make them excellent nanomaterials for theranostics, enabling the integration of targeting, imaging and therapeutics in a single platform, with proven applicability in the management of heterogeneous diseases, such as cancer. In this review, we focus on gold nanoparticle-based theranostics at the lab bench, through pre-clinical and clinical stages. With few products facing clinical trials, much remains to be done to effectively assess the real benefits of nanotheranostics at the clinical level. Hence, we also discuss the efforts currently being made to translate nanotheranostics into the market, as well as their commercial impact.

Cite

CITATION STYLE

APA

Pedrosa, P., Vinhas, R., Fernandes, A., & Baptista, P. V. (2015, November 3). Gold nanotheranostics: Proof-of-concept or clinical tool? Nanomaterials. MDPI AG. https://doi.org/10.3390/nano5041853

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free